U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07704580) titled 'Phase 1b/2 Study of IV Sarilumab in Adult With RA' on June 22.
Brief Summary: This is a Phase 1/Phase 2 study with:
* 5-arms design for Part A;
* and a single arm for Part B.
The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in male and female participants with moderately to severely active rheumatoid arthritis aged 18 years of age or older.
Study details include:
* The study duration will be up to 64 weeks.
* The treatment duration will be up to 6 months for each study phase....